洪少东

职称：医学博士、副主任医师、硕士生导师、广东省杰出青年基金获得者

专长：肺癌、鼻咽癌的个性化治疗、全程管理和耐药研究（化疗，免疫治疗及靶向治疗）、新药临床研究

出诊时间：最新出诊信息以挂号系统为准

个人简介：

中山大学医学博士（本硕博连读），荷兰癌症中心访问学者。擅长肺癌和鼻咽癌的化疗、靶向治疗和免疫治疗，尤其对罕见少见突变、靶向药、免疫治疗耐药和新药新方案等有深入研究。曾获得中国抗癌协会科技奖一等奖、广东省科学技术奖一等奖、广东医学科技奖一等奖、美国临床肿瘤学会（ASCO）抗癌基金奖、国际肺癌研究协会（IASLC）国际导师项目奖、中国临床肿瘤学会（CSCO）“全国35位最具潜力青年肿瘤医生”奖、第二届“人民好医生-金山茶花计划”肺癌领域优秀典范。是广东省杰出青年基金获得者。入选中山大学青年拔尖科研人才培育项目、中山大学附属肿瘤医院国家优青提升计划。近年来在国际顶尖杂志如《柳叶刀》、《柳叶刀-肿瘤学》、《美国医学会杂志-肿瘤学》、《自然-通讯》、《胸部肿瘤杂志》（国际肺癌研究协会官方期刊）、《癌症免疫治疗杂志》（癌症免疫治疗学会官方期刊）、《临床癌症研究》（美国癌症研究学会官方期刊）、《肺癌》（欧洲肿瘤医学会官方期刊）和《胸部肿瘤》（中华医学会肺癌分会、国际华人胸外科学会官方期刊）上发表SCI论著120余篇。研究结果被美国权威肿瘤治疗指南NCCN以最高证据级别收录。

学术兼职：

世界华人肿瘤医师协会胸部肿瘤专业青委会    委员

中国初级卫生保健基金会少见罕见突变肿瘤专委会 秘书长

中国初级卫生保健基金会少见罕见突变肿瘤专委会 秘书长

广东省胸部疾病学会肿瘤急危重症专委会    副主任委员

广东省保健学会免疫治疗专委会    副主任委员

广州抗癌协会肿瘤微环境专委会    副主任委员

所获荣誉和奖励：

美国临床肿瘤学会抗癌基金奖

国际肺癌研究协会国际导师项目奖

中国临床肿瘤学会“全国35位最具潜力青年肿瘤医生”

第二届“人民好医生-金山茶花计划”肺癌领域优秀典范

中国抗癌协会科技奖一等奖

广东医学科技奖一等奖（首届）

中山大学肿瘤附属肿瘤医院优秀青年抗癌医学科学奖

主持科研项目

国家级国家自然科学基金面上项目：EGFR突变-IRF7/cJun-CCL2轴调控肿瘤相关巨噬细胞在肺癌抗PD-1免疫治疗耐药中的作用和机制研究

国家级国家自然科学基金面上项目：EGFR突变调控肺癌微环境Treg活化介导抗PD1/PD-L1免疫治疗原发耐药的机制研究

国家级国家自然科学基金青年基金：p53对ALK基因融合介导的PD-L1调控的影响及其在肺癌免疫逃逸中的作用研究

省部级广东省自然科学基金杰出青年项目：EGFR突变调控肿瘤相关巨噬细胞介导肺癌PD-1抗体原发耐药的机制研究

省部级广东省自然科学基金面上项目：EGFR突变上调TGF-β1和GARP介导肿瘤微环境Treg活化及免疫治疗原发耐药的机制研究

高校基本科研业务费创新人才培育项目：EGFR突变调控肿瘤相关巨噬细胞介导肺癌PD-1抗体原发耐药的机制研究

中山大学青年教师培育项目：乏氧对驱动基因ALK介导的PD-L1调控的影响及其在非小细胞肺癌免疫逃逸中的作用

中山大学附属肿瘤医院国家优青提升计划：晚期肺癌的个体化治疗：化疗、靶向治疗、免疫治疗

代表性文章（节选；加粗为本人，^#第一作者，^*通讯作者）：

1. Zhang L^#, Huang Y^#, Hong S^#, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016 Oct 15;388(10054):1883-1892.
2. Fang W^#, Yang Y^#, Ma Y^#, Hong S^#, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018 Oct;19(10):1338-1350.
3. Hong S, ..., et al. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. Journal of Clinical Oncology, 2021 Oct 10, 39(29):3273-3282
4. Hong S^#, Gao F^#, Fu S^#, et al. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Mar 29
5. Hong S^#, Liu D^#, Luo S^#, et al. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat Commun. 2019 Jul 16;10(1):3108.
6. Li A^#, Wang Y^#, ..., Hong S^*. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC. Journal of Thoracic Oncology, 2023 Jul 24, S1556-0864(23)00688-3
7. Zhang X^#, Zhou Y^#, Chen C^#, …, Hong S^*, Zhang L^*. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer. 2019 Nov 21;7(1):322.
8. Li Z^#, Zhang X^#, Wang Y^#, ..., Hong S^*. Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2023 Oct;11(10):e007327.
9. Li A, ..., Hong S^*. Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy. NPJ Precision Oncology, 2023 Sep 11, 7(1):87.
10. He L^#, Li H^#, Du W^#, Fu S^#, Hong S^*. Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy. iScience, 2023 Jun 7, 26(7):107058.
11. Lin Z^#, Fu S^#, Zhou Y^#, …, Hong S^*. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma. Lung Cancer. 2019 Nov;137:100-107.
12. Fang W^#, Gan J^#, Hong S^#, et al. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC. J Thorac Oncol. 2019 Jul;14(7):e148-e151.
13. Fang W^#, Huang Y^#, Hong S^#, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer. 2019 Jun 17;19(1):595.
14. Fang W^#, Ma Y^#, Yin JC^#, Hong S^#, et al. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Aug 15;25(16):5015-5026.
15. Zhou Y^#, Lin Z^#, Zhang X^#, …, Hong S^*, Zhang L^*. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. J Immunother Cancer. 2019 May 3;7(1):120.
16. Zhou Y^#, Chen C^#, Zhang X^#, …, Hong S^*, Zhang L^*. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. J Immunother Cancer. 2018 Dec 22;6(1):155.
17. Zhao S^#, Zhang Z^#, Zhang Y^#, Hong S^#, et al. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. Int J Cancer. 2019 Jun 1;144(11):2854-2866.
18. Yang L^#, Xia L^#, Wang Y, …, Hong S^*, Chen Y^*. Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma. BMC Cancer. 2017 Sep 6;17(1):628.
19. Hong S^#, Zhang L. Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma. Chin J Cancer. 2016 Dec 22;35(1):100.
20. Hong S^#, Fang W^#, Hu Z^#, et al. A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. Sci Rep. 2014;4:7268.
21. Hong S^#, Tan M^#, Wang S^#, Luo S, Chen Y, Zhang L. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2015;141(5):909–921.
22. Zhang J^#, Qin T^#, Hong S^#, et al. Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma. Chin J Cancer. 2015;34(4):177–183.
23. Zhou T^#, Zhan J^#, Hong S^#, et al. Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer. Sci Rep. 2015;5:10481.
24. Xue C^#, Hong S^#, Li N, et al. Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment. Sci Rep. 2015;5:10648.
25. Liang W^#, Wu X^#, Hong S^#, et al. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. Coleman WB, ed. PLoS ONE. 2014;9(10):e109757.

更新日期：2023年10月26日